Turning Point Brands Q3 2026: Modern Oral Momentum Lifts Sales as EPS Dips Echo High-Year-Over-Year Comparisons

Ticker: TPB • EPS and Adjusted EPS figures highlighted, with revenue forecast reaffirmed for 2026

Quarterly snapshot and what it means for TPB and peers

Turning Point Brands, Inc. (TPB) reported its third-quarter 2026 results, underscoring a split personality within the portfolio. Total net sales rose 27% year over year to $151.1 million, led by a 52% surge in the Stoker’s segment to $113.8 million. By contrast, the Zig-Zag segment declined 15.5%, reminding investors that even within a diversified consumer-brands company, not all brands march in lockstep.

On the profitability line, gross profit advanced 20.9% to $85.2 million, supported by Modern Oral growth, while net income fell sharply, down 81.4% to $3.9 million. The year-over-year delta in net income reflects a tougher comparison base and ongoing investments, not a single line-item catastrophe. Diluted earnings per share stood at $0.19, with adjusted diluted EPS at $0.41, versus $1.13 and $1.05, respectively, in the prior-year quarter. In other words, EPS was not a story of outsized quarterly upside; it was a story of managing a higher-velocity growth engine while absorbing marketing and product-mix shifts.

Key financial highlights at a glance

Total Net Sales: $151.1 million, up 27.0% YoY
Stoker’s Net Sales: up 52.0% to $113.8 million
Zig-Zag Net Sales: down 15.5%
Gross Profit: $85.2 million, up 20.9%
Net Income: $3.9 million, down 81.4%
Adjusted EBITDA: $18.4 million, reflecting higher S&M investments
EPS (Diluted): $0.19; Adjusted EPS: $0.41
Prior-year EPS (GAAP / Adj.): $1.13 / $1.05
Guidance: FY 2026 revenue and EBITDA guidance reaffirmed

Brand mix and the path of a two-brand story

The company’s narrative hinges on Modern Oral growth within the Stoker’s segment, which drove the overall top line. Management notes that gross margin benefited from this mix, even as the Stoker’s business faced a margin backdrop shaped by shifting product mix toward Modern Oral products. The Zig-Zag portfolio, meanwhile, faced a more challenging period, illustrating how consumer-brand portfolios can outperform in some cycles and underperform in others depending on category timing, distribution, and promotional intensity.

From a data-sets perspective, the quarter reinforces a familiar pattern in consumer goods: growth drivers can be brand- and category-specific, while profitability tilts on the back of mix, investments, and scale. Investors should watch for whether Modern Oral continues to capture distribution and consumer engagement momentum, and whether Zig-Zag stabilizes or requires further strategic recalibration.

Guidance, investment, and what the numbers imply for 2026

Turning Point Brands reaffirmed its FY 2026 Modern Oral gross and net sales targets and EBITDA guidance, signaling confidence that the current trajectory is sustainable. The release explicitly notes increased investments in selling and marketing, which contributed to the Adjusted EBITDA figure. In practical terms, this means the company is choosing to invest ahead for growth in a high-growth segment, with the understanding that near-term profitability may bear the impact of these discretionary spends.

The earnings framework shows a classic tension: EPS for the quarter declined versus the prior-year period, while the company highlights progress in strategic bets (e.g., FRE and ALP initiatives) aimed at expanding distribution and consumer engagement in higher-growth categories. The reaffirmed revenue forecast and the deliberate investment cadence leave TPB positioned as a growth-focused enterprise that is willing to accept near-term margin pressure for longer-horizon gains.

Executive vantage point

“I have been involved with Turning Point Brands for nearly 14 years and have never been more optimistic about its future. I am very excited to serve as CEO at such an important time. We delivered another quarter of strong results, highlighted by continued growth in Modern Oral and progress across our heritage brands. Our investments in FRE and ALP are expanding distribution, strengthening consumer engagement and positioning us to become a leading player in the rapidly growing nicotine pouch category. We remain focused on this transformative opportunity to maximize long-term shareholder value.”

— David Glazek, Chief Executive Officer

Implications for TPB and sector peers

The quarterly mix—strong Modern Oral momentum, offset by a softer Zig-Zag line and a tough year-over-year earnings comparison—frames TPB as a barometer for the evolving nicotine and alternative consumer categories. The reaffirmed revenue forecast and the emphasis on ongoing investments in FRE and ALP could portend a multi-quarter growth narrative that outpaces general consumer-packaged-goods cycles if Modern Oral continues to gain shelf-space and consumer adoption.

For sector peers, the key signals include: how brands leverage category-tailwind opportunities (nicotine pouches, modern oral formats) while managing promotional intensity; how mix shifts influence gross margin and EBITDA; and how management communicates about investments in distribution and consumer engagement without over-promising on near-term earnings. In a market where the delta between top-line growth and bottom-line compression matters, TPB’s stance—growth-first with a clear path to profitability—could increasingly become a reference point for brand-led smokable alternatives and adjacent wellness-adjacent categories.

Risks and considerations

As with any company operating in nicotine-related consumer products, regulatory dynamics and evolving consumer preferences remain critical risk factors. The margin and earnings trajectory will depend on the pace at which Modern Oral products scale, how effectively distribution expands, and how marketing investments translate into sustainable revenue growth. The quarter’s results suggest a deliberate strategic path rather than a quick margin recovery, which will matter to investors monitoring EPS trajectories, the EPS consensus for TPB, and the stability of the revenue forecast for 2026 and beyond.

Bottom line

TPB’s Q3 2026 results present a nuanced picture: top-line growth driven by Modern Oral and Stoker’s, a meaningful year-over-year decline in net income and GAAP EPS, and a reaffirmed path toward its 2026 revenue and EBITDA targets. The narrative is less about a single blockbuster beat and more about disciplined execution in a portfolio supported by a strategic pivot toward higher-growth categories. For readers tracking EPS, EPS consensus, and the revenue forecast, TPB offers a case study in growth investments, brand mix management, and the evolving economics of a modern, multi-brand consumer company.